In this review, we discuss genetic, experimental, and clinical studies on the role of CD40 and CD40L in the neuroinflammatory response underlying MS and we explore novel strategies that may eventually overcome the current limitations of antagonizing the CD40–CD40L dyad in MS. The gene discussed is CD40; the disease is myeloid sarcoma.